# US 2014/0348866 A1 · Gb virus c (hepatitis g virus) for the treatment of hiv

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0348866 A1
- Document ID: US20140348866A1
- Status: Published application
- Kind: A1
- Application number: 14/460,517
- Filed: 2014-08-15
- Published: 2014-11-27
- Earliest claimed: 2003-06-05
- Assignees: University of Iowa Research Foundation; The United States of America, as represented by the Secretary, Department of
- Applicants: The University of Iowa Research Foundation; The United States of America AS Represented By the Secretary of the Department
- Inventors: Jack T. STAPLETON; Jinhua XIANG; Donna KLINZMAN; James H. McLINDEN
- Web page: https://patentgrep.com/patent/US20140348866A1

## CPC

- A61K 39/29: Hepatitis virus
- A61P 31/18: for HIV
- C07K 14/05: Epstein-Barr virus
- C07K 16/118: Hepatitis C virus; GB virus C [GBV-C]
- A61K 2039/505: {comprising antibodies}
- C07K 14/1841: {Hepatitis G; Hepatitis NANBNCNDNE}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2770/24222: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/24234: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

GB virus C (GBV-C or hepatitis G virus) is a flavivirus that frequently leads to chronic viremia in humans. The invention provides compositions and methods involving an anti-GBV-C antibody or other GBV-C binding agent, or a GBV-C antigen, for inhibiting and treating HIV infections.

## Claims

### Claim at position 1

1-27. (canceled)

### Claim 28

A vaccine composition comprising a GBV-C E2 polypeptide or peptide dispersed in pharmaceutical carrier, buffer or medium.

### Claim 29 (depends on 28)

The vaccine composition of claim 28, wherein the polypeptide or peptide is linked to a carrier molecule.

### Claim 30 (depends on 29)

The vaccine composition of claim 29, wherein the vaccine composition comprises an E2 peptide.

### Claim 31 (depends on 30)

The vaccine composition of claim 30, wherein the peptide has an amino acid sequence comprising FYEPLVRRC (SEQ ID NO: 8).

### Claim 32 (depends on 31)

The vaccine composition of claim 31, wherein the peptide has an amino acid sequence comprising LTGGFYEPLVRRC (SEQ ID NO:6).

### Claim 33 (depends on 32)

The vaccine composition of claim 32, wherein the peptide has an amino acid sequence comprising GGAGLTGGFYEPLVRRC (SEQ ID NO:7).

### Claim 34

A method of immunizing a subject comprising contacting said subject with a vaccine composition comprising a GBV-C E2 polypeptide or peptide dispersed in a pharmaceutical carrier, buffer or medium.

### Claim 35 (depends on 34)

The method of claim 34, wherein said vaccine composition further comprises an adjuvant.

### Claim 36 (depends on 34)

The method of claim 34, wherein said vaccine composition comprises an E2 polypeptide.

### Claim 37 (depends on 34)

The method of claim 34, wherein said vaccine composition comprises an E2 peptide.

### Claim 38 (depends on 37)

The method of claim 37, wherein the E2 peptide has an amino acid sequence comprising FYEPLVRRC (SEQ ID NO:8).

### Claim 39 (depends on 38)

The method of claim 38, wherein the E2 peptide has an amino acid sequence comprising LTGGFYEPLVRRC (SEQ ID NO:6).

### Claim 40 (depends on 39)

The method of claim 39, wherein the E2 peptide has an amino acid sequence comprising GGAGLTGGFYEPLVRRC (SEQ ID NO:7).

### Claim 41 (depends on 34)

The method of claim 34, wherein the polypeptide or peptide is linked to a carrier molecule.

### Claim 42 (depends on 28)

The vaccine composition of claim 28, wherein said vaccine composition further comprises an adjuvant.

### Claim 43 (depends on 28)

The vaccine composition of claim 28, wherein said vaccine composition comprises an E2 polypeptide.
